Entries |
Document | Title | Date |
20080200423 | Novel Tricyclic Nucleosides or Nucleotides as Therapeutic Agents - Nucelosides and nucleotides containing a tricyclic base portion thereof are useful for treating infectious diseases and proliferative disorders, such as viral infections or cancer respectively. | 08-21-2008 |
20080200424 | Preparation for Treating Cancer - The present invention relates to a combined preparation that is effective against cancerous cells containing as the active substances at least one 1-diethylaminoethyl-3-quinoxalin-2-one derivative of formula | 08-21-2008 |
20080200425 | Methods and compositions for regulating bone mineral density - A method for treating or preventing osteoporosis or a medical condition associated with a reduced or loss of bone mineral density and its related complications, in a mammalian subject is accomplished by intravenously administering to the mammalian subject, a therapeutically effective amount of a sterile aqueous liposomal suspension of lipoprotein small unilamellar vesicles (SUVs) comprising predominantly phospholipids. When the sterile aqueous liposomal suspension is administered to the subject, an increase of bone mineral density is observed over the time of observation. | 08-21-2008 |
20080214492 | Folate based composition for treatment of the cardiovascular system - New formulations for the prevention and treatment of cardiovascular diseases arthrosclerosis and risk factors thereof including elevated cholesterol and blood pressure levels comprise phytosterols, flavones and folate, alone or in combination, along with additional compounds chosen to address some or all of the pathways which can result in cardiovascular diseases, namely inflammation, oxidative stress, glycation/dysinsulinemia, platelet function, and homocysteine levels that are important contributors to the development or progression of CVD. | 09-04-2008 |
20080227746 | Methods and Compositions for Treatment of Excess Nitric Oxide or Cyanide Toxicity - Methods for treating disease states in a subject caused or exacerbated by the presence of excess nitric oxide (NO) or excess cyanide are provided. Methods for alleviating the symptoms of a disease state in a subject caused or exacerbated by the presence of excess nitric oxide (NO) or excess cyanide in the subject are also provided. Pharmaceutical compositions comprising cobinamide and a pharmaceutically acceptable carrier are also provided. | 09-18-2008 |
20080255067 | CYANOCOBALAMIN LOW VISCOSITY AQUEOUS FORMULATIONS FOR INTRANASAL DELIVERY - A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin. | 10-16-2008 |
20080261914 | STABILIZATION OF VITAMIN B12 - The invention relates to preparations comprising vitamin B | 10-23-2008 |
20090012039 | Use of methylcobalamin nasal spray to treat disorders - A method of treating a disorder by nasally administering methylcobalamin, with or without folinic acid. The disorders addressed are: a) attention deficit hyperactivity disorder (ADHD); b) anxiety, depression, stress and chronic stress; c) socialization problems, mood problems, behavior problems, memory problems; d) dislexia, depth perception problems, color viewing problems, visual and auditory processing problems, light modulation problems, night vision problems; e) speech problems such as finding words, apraxia, and articulation problems, sleep regulation problems, eye or muscle movement problems; and f) chronic fatigue problems, digestion problems, sensitivity to chemicals, viral infection, inflammatory conditions such as rheumatoid arthritis, sciatica, and fibromyalgia, asthma, irritable bowel, colitis, tinnitus, migraines, nail biting, autoimmune problems. In some embodiments, the disorders that are particularly addressed are ADHD, anxiety, stress and chronic stress, and irritable bowel. | 01-08-2009 |
20090054371 | FOLIC ACID-, VITAMIN B6- AND VITAMIN B12-CONTAINING AGENTS AND THE USE THEREOF - The invention relates to agents containing a folic acid, vitamin B6 and vitamin B12 and to the use thereof in hyperhomocystenemia for controlling homocysteine levels. The inventive agents are particularly suitable for preventive and acute treatment of vascular diseases of pregnant women and neurodegenerative diseases and are particularly advantageous in cases of hyperhomocysteinemia whose treatment with homocysteine level reducing agents causes secondary effects. Pharmaceutical agents and food supplements comprising the corresponding active substance combination, agents in the form of commercial packages containing corresponding combination preparations or monopreparations for a combined application are, in particular, also disclosed. | 02-26-2009 |
20090054372 | Combination therapy for weight loss - The present invention is directed to methods and kits for achieving or maintaining weight loss. These kits and methods can include administering a pharmaceutical composition comprising phentermine, topiramate and a B vitamin to a subject in need thereof. | 02-26-2009 |
20090075932 | METHOD OF SELECTIVELY INHIBITING PKCiota - PKCiota inhibitor 1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl]-,[1R-(1α,2β,3β,4α)], (ICA-1), targets a unique sequence (amino acid residues 469-475) in the catalytic domain of PKCiota and inhibits PKCiota activity. The data shows suprising and unexpected ability of ICA-1 to selectively inhibit the proliferation of cells that overexpress PKCiota. | 03-19-2009 |
20090124572 | Iron-containing nutritional supplement - The present invention relates to a nutritional supplement, and particularly, to an oral nutritional supplement which contains an iron fortificant comprising a ferric pyrophosphate chelate. The nutritional supplement can also include vitamins, non-ferrous minerals, and other ingredients. The nutritional supplement is useful for providing iron to animals, and is intended to be used, for example, to administer iron to animals and humans, including individuals afflicted with anemia of chronic disease, pregnant women, women anticipating pregnancy, and lactating women. The compositions and methods can also be used to administer iron together with one or more vitamins or non-ferrous minerals to men, women, children or infants, as well as to animals. | 05-14-2009 |
20090137523 | Compositions for External Application, Containing Adenosyl Cobalamin for Improvement of Skin Diseases - The present invention relates to a composition for external application for improving a skin disease (e.g. psoriasis). Said composition contains adenosyl cobalamin (coenzyme B12), opt. in admixture with other cobalamins. Preferable said composition is present in the form of liposomal preparations, which are made of a phospholipid and cholesterol. | 05-28-2009 |
20090239818 | EFFECTIVE TREATMENT OF OVARIAN CANCER USING TRICIRIBINE AND RELATED COMPOUNDS - The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat ovarian cancer by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug. The invention further encompasses a number of miRNAs, which are altered in human ovarian cancer, with the most significantly deregulated miRNAs being miR-214, -199a*, -200a, -100, -12Sb, and let-7 cluster. Further, the invention illustrates that frequent deregulation of miR-214, -199a*, -200a and -100 in ovarian cancers and their alterations are associated with high grade and late stage tumor. Significantly, miR-214 induces cell survival and cisplatin resistance through targeting 3′UTR of the PTEN, which leads to down regulation of PTEN protein and activation of Akt pathway. Inhibition of Akt using Akt inhibitor, API-2/triciribine, or introduction of PTEN cDNA lacking 3′UTR largely abrogates miR-214 induced cell survival. These findings indicate that deregulation of miRNAs is a recurrent event in human ovarian cancer and that miR-214 induces cell survival and cisplatin resistance primarily through targeting the PTEN/Akt pathway. | 09-24-2009 |
20090253649 | Agents Containing Folic Acid, Vitamin B6 and Vitamin B12, and the Use Thereof - (EN) The invention relates to agents that contain folic acid, vitamin B6 and vitamin B12. and to the use thereof in hyperhomocysteinemia for controlling homocysteine levels. The agents are mainly suitable for the preventive and acute treatment of vascular diseases, of pregnant women and neurodegenerative diseases and are particularly advantageous in cases where the homocysteine levels to be controlled are found in an individual suffering from renal failure or being treated with immune suppressors. The invention particularly relates to pharmaceutical agents and food supplements comprising a corresponding active ingredient combination and to agents in the form of commercial packages containing corresponding combination preparations or monopreparations for the combined use. | 10-08-2009 |
20090291910 | AGENT AND FOOD FOR PREVENTING/IMPROVING FUNCTIONAL DIGESTIVE DISORDER - The present invention provides an agent and a food for the prophylaxis or improvement of a functional gastrointestinal disorder, which contains, as an active ingredient, at least one kind selected from glutamic acid, 5′-nucleotide and a salt thereof. | 11-26-2009 |
20100016255 | METHOD OF TREATING VITAMIN B12 DEFICIENCY - A novel method and composition for treating vitamin B | 01-21-2010 |
20100016256 | Taxane Compounds for Treating Eye Disease - The present invention is directed to methods of treating eye disease. In one embodiment, the method can comprise administering a taxane-cobalamin bioconjugate or another taxane compound to a subject to treat the eye disease. In one embodiment, the bioconjugate can be dissolved in an aqueous solution prior to administration. | 01-21-2010 |
20100035836 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS - The present disclosure relates to the use and methods of manufacture of bicyclic nucleosides and nucleotides for the treatment and prevention of infectious and proliferative diseases, including microbial infections and cancer. | 02-11-2010 |
20100041622 | Compositions containing aminoalkanes and aminoalkane derivatives - Provided are palatable liquid compositions that contain 2-aminoalkanes that have vasoconstrictor activity, and other additives, including taste-modifying agents. Also provided are methods for making and using the compositions to provide stimulant activity for increasing energy, alertness, endurance, and/or any other consequent physical manifestation of the vasoconstrictor activity. | 02-18-2010 |
20100113381 | EFFECTIVE TREATMENT OF ESOPHOGEAL ADENOCARCINOMA USING TRICIRIBINE AND RELATED COMPOUNDS - The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat esophogeal adenocarcinoma by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug. | 05-06-2010 |
20100130441 | USE OF VITAMIN B12 FOR TREATMENT OF MUCOSAL LESIONS - The present invention relates to the use of the nutrition supplement known as vitamin B12 (cobalamin) to treat or prevent mucosal lesions. It relates particularly to treatment of mucosal lesions and prevention of development of recurrent mucosal lesions by the repeated administration over a period of time of vitamin B12 where a subject has normal, or above normal, serum vitamin B12 levels. Compositions (medicaments), including friendly carriers (e.g. chewing gum), and kits, for vitamin B12 delivery to mucosal lesions or other injuries are also provided. | 05-27-2010 |
20100137240 | USE OF NUCLEOSIDE DERIVATIVES AS ANTI-KOI HERPES VIRUS IN FISH - The present invention relates to the use of N-phosphonylmethoxyethyl nucleoside analogs for manufacturing a medicament for the treatment or prevention of Koi Herpes virus infections in fish, especially in carps. | 06-03-2010 |
20100168053 | ORAL DELIVERY SYSTEM FOR METHYLCOBALAMIN TO TREAT DISORDERS - A method of treating a disorder by lollipop administering methylcobalamin, with or without folinic acid by direct delivery to the trigeminal nerve. The disorders addressed are: a) attention deficit hyperactivity disorder (ADHD); b) anxiety, depression, stress and chronic stress; c) socialization problems, mood problems, behavior problems, memory problems; d) dyslexia, depth perception problems, color viewing problems, visual and auditory processing problems, light modulation problems, night vision problems; e) speech problems such as finding words, apraxia, and articulation problems, sleep regulation problems, eye or muscle movement problems; and f) chronic fatigue problems, digestion problems, sensitivity to chemicals, viral infection, inflammatory conditions such as rheumatoid arthritis, sciatica, and fibromyalgia, asthma, irritable bowel, colitis, tinnitus, migraines, nail biting, autoimmune problems. In some embodiments, the disorders that are particularly addressed are ADHD, anxiety, stress and chronic stress, and irritable bowel. A lollipop for treating a psychological or neuro-physiological disorder and method of making thereof. | 07-01-2010 |
20100184719 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES - Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are potent CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In formula I, A-B is an arylamide moiety. | 07-22-2010 |
20100190739 | Rapidly Dissolving Vitamin Formulation and Methods of Using the Same - Rapidly dissolvable nutritional compositions and methods of providing nutritional supplementation to candidates for, patients undergoing, or patients having undergone bariatric surgery, to patients suffering renal disease, and to candidates for or patients undergoing dialysis. The compositions generally comprise one or more vitamins and optionally minerals and dissolve in less than about 90 seconds upon oral administration. | 07-29-2010 |
20100197630 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES - Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are potent CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In formula I, A-B is an arylamide moiety. | 08-05-2010 |
20100210580 | Vitamin B12 Nasal Spray and Method of Use - The present invention relates generally to vitamin B | 08-19-2010 |
20100210581 | Nucleoside Derivatives as Inhibitors of Viral Polymerases - A class of nucleoside derivatives of formula (I), as defined herein, that are useful as inhibitors of RNA-dependent RNA viral replication and in particular HCV replication, are provided. Also provided are processes for the synthesis and use of such compounds for treating or preventing HCV infection. | 08-19-2010 |
20100210582 | METHOD AND COMPOSITION FOR TREATING PATIENTS WITH A HIGH RISK OF DEVELOPING NEURO-IMMUNE DISORDERS OR DEVELOPMENTAL DELAYS, IDENTIFIED THROUGH THE UTILIZATION OF LOW HOMOCYSTEINE OR ITS PRECURSORS/METABOLITES, AS THE PREDICTOR OF SUCH RISK - A method for predicting the likelihood of developing ASD and ASD-related diseases in a subject is disclosed. The method includes the steps of measuring the level of homocysteine, a homocysteine precursor or a homocysteine metabolite in the subject and evaluating the likelihood of developing ASD and ASD-related diseases based on the result of measurement. A subject is deemed to have a high risk of developing ASD and ASD-related diseases if the level of homocysteine, the homocysteine precursor or the homocysteine metabolite in the subject is at or below a threshold level. Also disclosed are a composition for reducing the risk of developing ASD, ASD-related diseases and adult neurological abnormalities and a method for determining a vaccination schedule in a subject. | 08-19-2010 |
20100210583 | NOVEL ANTIFOLATE COMBINATION THERAPIES - A method of administering an antifolate to a mammal in need thereof, comprising administering an effective amount of said antifolate in combination with a methylmalonic acid lowering agent. | 08-19-2010 |
20100286084 | Oligomer-Nucleoside Phosphate Conjugates - The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble, non-peptidic oligomer. The conjugates of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds. | 11-11-2010 |
20100298258 | ANALGESIC COMPOSITIONS - Embodiments of the invention relates to pharmaceutical compositions for use in the treatment of pain and inflammation in mammals, including humans, by administering compositions comprising i) an effective amount of an analgesic having an optional anti-inflammatory effect; (ii) an amount of caffeine effective in enhancement of pain relief; and, (iii) an amount of B vitamins effective in enhancement of pain relief. | 11-25-2010 |
20110015150 | METHODS OF ADMINISTERING COMPOSITIONS INCLUDING IRON - Nutritional or dietary supplement compositions that promote and/or maintain dietary iron absorption through administration of iron with an organic acid and optionally similar iron absorption promoters are provided. Also provided are methods of nutritional or dietary supplementation using one or more compositions that promote and/or maintain health through the prevention, stabilization, reversal and/or treatment of disorders associated with iron deficiency. | 01-20-2011 |
20110065665 | STABILIZATION OF VITAMIN B12 - The invention relates to preparations comprising vitamin B | 03-17-2011 |
20110071101 | Nucleoside Phosphonate Analogs - The invention is related to phosphorus substituted nucleoside compounds and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 03-24-2011 |
20110071102 | Compositions and Methods to Treat Recurrent Medical Conditions - The invention describes methods and compositions for alleviating recurrent medical afflictions for which anxiety may cause or exacerbate the affliction. A subject suffering from the affliction is treated with a combination of a pharmaceutical that enhances learning, and a second pharmaceutical recognized to be useful for treatment of the affliction. Representative afflictions include insomnia, erectile dysfunction, female sexual dysfunction, neuropathic pain, attention deficit disorder, and depression. | 03-24-2011 |
20110092454 | Methods For Treating Mycoplasma Related Conditions In Livestock - The present invention provides methods and related kits for treating or preventing a | 04-21-2011 |
20110112047 | METHODS FOR ENHANCING MUSCLE PERFORMANCE AND TONE - This disclosure concerns the use of agonists of AMP-activated protein kinase (AMPK) for improving exercise and modifying energy metabolism in a subject. The disclosure also relates to a combination of AMPK and peroxisome proliferator-activated receptor (PPAR) δ agonists for improving exercise performance in a subject, methods for identifying substance-enhanced exercise performance in a subject, and methods for identifying compounds that affect the interaction of PPARδ with exercise-induced kinases. | 05-12-2011 |
20110166097 | TAXANE COMPOUNDS FOR TREATING EYE DISEASE - The present invention is directed to methods of treating eye disease. In one embodiment, the method can comprise administering a taxane-cobalamin bioconjugate or another taxane compound to a subject to treat the eye disease. In one embodiment, the bioconjugate can be dissolved in an aqueous solution prior to administration. | 07-07-2011 |
20110172179 | Micronutrient formulations for radiation applications - A radioactive protection micronutrient formulation system is provided and the system comprises: a formulation consisting essentially of antioxidants, the antioxidants are selected from the group consisting essentially of vitamin C, vitamin E, N-acetyl cysteine, natural mixed carotenoids, and alpha-lipoic acid, vitamin A (palmitate), vitamin D-3 (cholecalciferol), thiamine mononitrate, riboflavin, niacinamide ascorbate, d-calcium pantothenate, pyridoxine hydrochloride, cyanocobalamin, folic acid, D-Biotin, selenium (1-seleno-methionine), chromium picolinate, zinc glycinate, calcium citrate and magnesium citrate and mixtures thereof; and plus a booster formulation selected from a group consisting essentially of vitamin C, d-alpha tocopheryl acid succinate, alpha tocopherol, N-acetyl cysteine, natural mixed carotenoids and alpha lipoic acid, the formulation is designed to reduce the risk in humans exposed to doses of ionizing radiation of becoming subjected to at least one condition selected from the group consisting essentially of radiation-induced acute leukemia, breast cancer, thyroid cancer and other somatic and heritable mutations. | 07-14-2011 |
20110207693 | Oral B12 Therapy - Methods of normalizing vitamin B | 08-25-2011 |
20110275591 | COCKTAIL FOR MODULATION OF ALZHEIMER'S DISEASE - Formulations for the prevention and treatment of neurological diseases and cognitive deficiencies, i.e., Alzheimer's Disease (AD), Parkinson's Disease, amyotrophic lateral sclerosis, mild cognitive impairment and other types of dementia, comprise therapeutically effective amounts of curcumin, piperine, epigallocatechin-3-gallate (EGCG) and one or more of N-acetylcysteine, benfotiamine and alpha-lipoic acid. The combination addresses some or all of the pathways which can result in neurological deficiencies, degeneration and diseases. | 11-10-2011 |
20110306573 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF VIRAL POLYMERASES - Compounds of structural formula (I): and pharmaceutically acceptable salts thereof; wherein R | 12-15-2011 |
20110319356 | Methods Of Treating Optic Disorders - The present invention relates to methods for treating optic disorders or for reducing or alleviating the signs, symptoms, or pathological conditions related to such optic disorders. In particular, methods are provided for treating optic disorders, or reducing the symptoms thereof, the methods involving the administration of one or more downstream folate compounds and/or methyl-B12. In one particular embodiment, the method comprises administration of L-methylfolate. In other embodiments, the method involves administering both L-methylfolate and methyl-B12. In still further embodiments, the method further involves reducing dietary intake of folic acid. In certain embodiments, the method further involves identifying a subject organism with a malfunction in one or more of the folate or B4 cycles. In certain embodiments, such a malfunction is one or more of the C677T and A1298C mutations. In still further embodiments, the method further involves identifying a subject organism that is deficient in vitamins B-12 and D3 but which possesses excess homocysteine. | 12-29-2011 |
20120015900 | Cobalamin Taxane Bioconjugates - The present invention is directed to methods and compositions including a taxane covalently bonded to the cobalt atom of a cobalamin. The composition can be delivered by any effective route, but is particularly useful as an oral anti-cancer or antiangiogenic compound. The anti-cancer/anti-angiogenic compound can be used in various chemotherapies including anti-angiogenic chemotherapies, alone or in combination with other anti-cancer/anti-angiogenic compounds. | 01-19-2012 |
20120022015 | METHOD OF TREATMENT AND SUPPLEMENT - A method of treatment and associated nutritional combination is disclosed. The method of treatment includes providing a patient with a nutritional combination including appropriate amounts of riboflavin, pyridoxine hydrochloride, and cyanocobalamin. The combination may further include thiamine mononitrate and calcium pantothenate, and may be in the form of an oral supplement such as a capsule or tablet. Alternatively, the combination may be a fluid for intravenous intake, and may further include thiamine hydrochloride, D-panthenol, water, benzyl alcohol, and sodium chloride. The treatement and combination of ingredients works synergistically together and is particularly effective in enhancing nerve regeneration in a variety of patients. | 01-26-2012 |
20120108535 | 2-FLUORINATED RIBOSES AND ARABINOSES AND METHODS OF USE AND SYNTHESIS - Disclosed are halogenated 2-deoxy-lactone, 2′-deoxy-nucleosides, and derivatives thereof, for example, a compound of formula (I). Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one compound or salt of the invention, and a method of treating a disorder is selected from the group consisting of an abnormal cellular proliferation, a viral infection, and an autoimmune disorder. | 05-03-2012 |
20120122811 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS - The present disclosure relates to the use and methods of manufacture of bicyclic nucleosides and nucleotides for the treatment and prevention of infectious and proliferative diseases, including microbial infections and cancer. | 05-17-2012 |
20120129801 | BLOOD PARASITICIDE - This application relates to compositions and methods of treating tick-born parasitic diseases in livestock with the compositions. The compositions include imidocarb dipropionate, cyanocobalamin vitamin B12, and pharmaceutically acceptable carriers. | 05-24-2012 |
20120157405 | Methods and Compositions for the Treatment of "Burning Feet Syndrome" - A composition for the treatment of “Burning Feet Syndrome” includes pantothenic acid or its analogs, or its derivatives, or its synonyms, alpha-lipoic acid or its analogs, or its derivatives, or its synonyms, and L-arginine or its analogs, or its derivatives, or its synonyms. The composition may also include at least one substance selected from the group consisting of B1, B2, B3, B6, B7, B9, B12, Acetly-L-Carnitine, N-acetlycystein, Omega-3 fatty acids, Omega-6 fatty acids, Vitamin E, and Taurine or any of their analogs, derivatives, or synonyms. The composition is used in a method for the treating of “Burning Feet Syndrome” by administering to a human such a composition. | 06-21-2012 |
20120190640 | CYANOCOBALAMIN LOW VISCOSITY AQUEOUS FORMULATIONS FOR INTRANASAL DELIVERY - A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering, intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin. | 07-26-2012 |
20120225840 | HYDROXYTYROSOL COMBINATIONS FOR ENHANCING MITOCHONDRIAL FUNCTION AND ENERGY PRODUCTION - Hydroxytyrosol or olive juice containing hydroxytyrosol in combination with at least one of the compounds selected from the group consisting of: creatine, coenzyme Q10, resveratrol, caffeine, carnitine, B vitamins (B1, B2, B3, B5, B6, and/or B12) and ginseng (preferably: root) extract can be used to maintain or increase mitochondrial biogenesis in cardiac muscle, skeletal muscles, and liver tissue. | 09-06-2012 |
20120277179 | Edible Energy Composition - The disclosure relates to an edible energy composition that provides physical and mental benefits when ingested. | 11-01-2012 |
20120277180 | Cofactors and Methods for Use for Individuals - Provided herein are methods and systems for identifying one or more cofactors such as vitamins for individuals based on the genetic makeup of the individual by detecting the presence or absence of at least one genetic variant, determining a predisposition to cofactor remediable condition, generating a personalized nutritional advice plan based on the genetic variant. Also provided herein are formulations of cofactors determined by the genetic make-up of the individual and methods of determining and producing these formulations. | 11-01-2012 |
20120289476 | METHODS FOR TREATING METHYLMALONIC ACIDEMIA - Methods for treating methylmalonic acidemia in which at least one allele of a gene associated with MMA (e.g., the MUT, MMAA, or MMAB gene) contains a mutation (e.g., nonsense mutation) that results in a premature stop codon in RNA encoded by an allele of the gene associated with MMA involving the administration of a compound that promotes readthrough of RNA (e.g., messenger RNA) containing a premature stop codon encoded by an allele of the gene associated with MMA are described. The compound can be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment. | 11-15-2012 |
20120329748 | ACTIVATION AND ACTIVATORS OF SIRT5 - The invention provides a method of increasing a deacetylase activity of SIRT5 by contacting SIRT5 with an agent that binds SIRT5 and reduces the K | 12-27-2012 |
20120329749 | Methods Of Preventing Or Treating Disease States Related To Certain Metabolic Abnormalities - The present invention relates to methods of treating, preventing, and/or improving disorders and conditions related to certain metabolic abnormalities including methods of improving blood lipid profiles and muscle recovery and repair in athletes, methods of treating fibromyalgia, erectile dysfunction, diseases associated with certain HLA-DQ gene alleles and/or gluten intolerance, including Celiac Disease, headaches and migraines, as well as idiopathic neuropathy, inability to sleep, inability to concentrate, and/or neurological development issues in children, the methods involving the administration of one or more downstream folate compounds and optionally methyl-B12. In one particular embodiment, the method comprises administration of L-methylfolate. In certain embodiments, the method further involves identifying a subject organism with a malfunction in one or more of the folate or B4 cycles. In certain embodiments, such a malfunction is one or more of the C677T and A1298C genetic polymorphisms. | 12-27-2012 |
20130005679 | Multivitamin Compositions and Methods for Improving Health - Provided are multivitamin compositions comprising vitamin B1, vitamin B2, vitamin B5, vitamin B6, vitamin B12, folic acid, magnesium glycinate, and selenium. These compositions are effective and natural treatments for improving health in a mammal. In some embodiments, the multivitamin compositions are administered to a female mammal to normalize a menstrual cycle. In other embodiments, the multivitamin compositions are administered to treat a sleep disorder. | 01-03-2013 |
20130018013 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS - The present disclosure relates to the use and methods of manufacture of bicyclic nucleosides and nucleotides for the treatment and prevention of infectious and proliferative diseases, including microbial infections and cancer. | 01-17-2013 |
20130029930 | ACTIVATION AND ACTIVATORS OF SIRT6 - The invention provides a method of increasing a deacetylated activity of SIRT6 by contacting SIRT6 with an agent that binds SIRT6 and reduces the K | 01-31-2013 |
20130040910 | METHOD OF TREATING VITAMIN B12 DEFICIENCY - A novel method and composition for treating vitamin B | 02-14-2013 |
20130059813 | TREATMENT OF DERMATOLOGICAL CONDITIONS - The present disclosure provides a method for treating dermatological conditions, such as psoriasis, dermatitis, and dandruff. Said conditions are treated by administering to a person a vitamin supplement composition comprising folic acid, vitamin B | 03-07-2013 |
20130090304 | COMPOSITIONS INCLUDING TRICIRIBINE AND TAXANES AND METHODS OF USE THEREOF - This application relates to combination therapies including triciribine and related compounds and taxanes and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. | 04-11-2013 |
20130090305 | METHOD USING A DIETARY SUPPLEMENT FOR HEALING OR REGRESSING SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE, GASTRITIS AND ULCERS - The current invention presents a dietary supplement obtained from a mixture of melatonin, vitamins and aminoacids and administered for healing or regressing the symptoms of gastroesophageal reflux disease, such as heartburn, regurgitation, dysphagia, coughing, hoarseness, chest pain and odynophagia, gastritis and several types of ulcerations. | 04-11-2013 |
20130109648 | METHOD FOR TREATING A HUMAN PATIENT SUFFERING FROM MYELOID NEOPLASIAS USING 5-AMINOIMIDAZOLE-4-CARBOXAMIDE | 05-02-2013 |
20130109649 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | 05-02-2013 |
20130137655 | Cytochrome P450 Enzyme Complexes And Methods Of Treatment Using The Same - The present invention provides methods and compositions for balancing electron reduction potentials of formulations in a manner that reduces susceptibility to changes from xenobiotics. The present invention also provides novel compositions of matter based on structuring from a mobile nucleotide integral to its architecture. | 05-30-2013 |
20130143836 | PHARMACEUTICAL COMPOSITION FOR TREATING COAGULATION DISORDER HEMORRHAGE AND METHOD USING THE SAME - Pharmaceutical composition for treating hemorrhage caused by blood clotting disorder and use thereof. The pharmaceutical composition comprises (per unit): L-ornithine 0.5-8 g, aspartic acid 1-5 g, arginine 3-10 g and vitamin B6 3-10 g. The pharmaceutical composition can treat hemorrhage caused by blood clotting disorder effectively and is very appropriate for treating patient at stake. | 06-06-2013 |
20130178441 | Methods for Extending Progression-Free Survival using 10-Propargyl-10-Deazaaminopterin - The present invention includes a method to reverse the trend towards progressive resistance to consecutive treatments for T-cell lymphoma in a patient. This method includes selecting a patient having T-cell lymphoma, wherein the patient has had at least one prior treatment for T-cell lymphoma, wherein the prior treatment comprises non-10-propargyl-10-deazaaminopterin; and administering to the patient a composition comprising a therapeutically effective amount of 10-propargyl-10-deazaminopterin, whereby the trend towards progressive resistance is reversed. | 07-11-2013 |
20130184233 | Personal Lubricant Compositions - A skin lubrication lotion that functions as a skin rubbing anti-friction barrier compound to prevent skin rashes from burning of skin from excessive rubbing, said lotion comprising: a lubricant; a skin numbing ingredient including lidocane; a vitamin ingredient, wherein the vitamin is selected from the group consisting of vitamin A, C, E, D or B 12; an ingredient that causes human skin to tingle, wherein the tingling ingredient is selected from the group consisting of menthol and L-arginine ethyl ester; wherein the skin lotion further consisting essentially of about: 71% water, 0.070% sodium benzoate, 0.070% potassium Sorbate, 0.180% citric acidanhydrous (FCC, USP), 14.200% glycerine 99.7%, 14.200% propylene glycol USP, 0.140% Xanthan gun 80 mesh, and 0.140% guar gun 250 (food grade). | 07-18-2013 |
20130210758 | FORMULATION AND METHOD TO INDUCE A DEEP STATE OF RELAXATION - A relaxation formulation structured to induce a deep state of relaxation in a person comprises amounts of tryptophan, melatonin, vitamin B3, and vitamin B6. Another relaxation formulation also includes an amount of tyrosine, and yet another formulation includes an amount of vitamin B12. At least one embodiment of a relaxation formula comprises a physiologically effective amount of gamma-aminobutyric acid (“GABA”). A delivery system is provided to facilitate administration of the relaxation formulation to a person. The delivery system may include an edible high carbohydrate matrix, such as a chocolate brownie. Alternatively, the delivery system may comprise an inert vaporizable compound to allow the components of the relaxation formulation to be inhaled directly into the lungs of a person. Other delivery systems include an aqueous sublingual spray and a beverage. | 08-15-2013 |
20130225521 | PREVENTION OF MICRONUTRIENT DEFICIENCIES ASSOCIATED WITH COMMON DISABILITIES IN THE OVER 50 ADULT - A micronutrient dosage unit which comprises two or more micronutrients selected from vitamin A, vitamin B | 08-29-2013 |
20130281401 | COMBINATION THERAPY FOR THE TREATMENT OF DEPRESSION AND OTHER NON-INFECTIOUS DISEASES - The invention relates to methods, uses and compositions for treating non-infectious diseases with a therapeutically effective amount of a pharmaceutical composition comprising methylsulfonylmethane, glucosamine, L-glycine, and vitamin B | 10-24-2013 |
20130324496 | SOLID FORMS OF AN ANTIVIRAL COMPOUND - Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: | 12-05-2013 |
20140073598 | MULTIPLE FOLATE FORMULATION AND USE THEREOF - A multiple folate composition having at least 3 different forms of folate comprising at least one of folic acid (a salt or ester thereof); at least one of a folinic acid (a salt or ester thereof); and at least one of a 5-methyl-tetrahydrofolic acid (a salt or ester thereof) is disclosed. The composition is useful as a nutritional supplement or medication in the treatment of folate deficiency and the sequella thereof and/or in conditions responsive to administration of metabolically useful folate. The compositions are particularly of use in patients who have impaired or reduced ability to convert folic acid to its metabolically active forms, and in the treatment of depression. | 03-13-2014 |
20140088035 | TREATING SCHIZOPHRENIA - The specification provides methods of treating a subject suffering from a negative symptom of schizophrenia and methods of determining whether a subject is suffering from or at risk for developing a negative symptom of schizophrenia. | 03-27-2014 |
20140142060 | METHOD AND DEVICE FOR IDENTIFICATION OF ONE CARBON PATHWAY GENE VARIANTS AS STROKE RISK MARKERS, COMBINED DATA MINING, LOGISTIC REGRESSION, AND PATHWAY ANALYSIS - The disclosure provides method and device using a whole genome association analysis toolset for a total stroke case, versus a control group, which demonstrated significant associations with p less than 1.00E.03 for 5 genes, including polymorphisms in MTHFR, MTRR, and BHMT. These gene polymorphisms in MTHFR may remove or create intron and exon splice enhancer sites that affect alternative splicing activity as well as appropriate mRNA and protein production. | 05-22-2014 |
20140235569 | COMPOSITION AND METHODS FOR THE PRODUCTION OF S-ADENOSYLMETHIONINE WITHIN THE BODY - Described herein is a method for increasing levels of S-adenosylmethionine within the human body without administering S-adenosylmethionine directly. The method of the invention may be achieved by administering one or more of L-methionine, methylcobalamin, 5-Methyl tetrahydrofolate, betaine, and malic acid, together with at least one compound selected from the group consisting of folic acid, vitamin B12, magnesium, calcium, and other cofactors. | 08-21-2014 |
20140315853 | METHODS, FORMULATIONS, AND KITS FOR RAPIDLY REPLETING FOLATE LEVELS IN WOMEN - Disclosed are methods for rapidly repleting folate levels of a woman for whom there is reason to believe that she may be pregnant or of a woman who believes that she may soon become pregnant. One of the methods includes administering to the woman two or more repletion doses of folate, wherein each of the repletion doses comprises no less than about 2.5 micromole of folate, wherein the repletion doses are administered no more than about one day apart, and wherein the total number of repletion doses administered to the woman is 72 or fewer. | 10-23-2014 |
20140323428 | ANTINEURITIC PHARMACEUTICAL COMBINATION AND COMPOSITIONS - The present invention refers to pharmaceutical combinations of two antiepileptic substances and also to combinations of an antiepileptic and B-complex vitamins, in which the antiepileptic substances are selected from pregabalin and oxcarbazepine, and the vitamins are selected from vitamin B1 and vitamin B12. The invention also relates to pharmaceutical compositions containing said combinations and to the use of said compositions for treating neuropathic pain (NP). | 10-30-2014 |
20140343009 | METHODS FOR TREATING METHYLMALONIC ACIDEMIA - Methods for treating methylmalonic acidemia in which at least one allele of a gene associated with MMA (e.g., the MUT, MMAA, or MMAB gene) contains a mutation (e.g., nonsense mutation) that results in a premature stop codon in RNA encoded by an allele of the gene associated with MMA involving the administration of a compound that promotes readthrough of RNA (e.g., messenger RNA) containing a premature stop codon encoded by an allele of the gene associated with MMA are described. The compound can be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment. | 11-20-2014 |
20140371168 | OLIGOMER-NUCLEOSIDE PHOSPHATE CONJUGATES - The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble, non-peptidic oligomer. The conjugates of the invention, when administered by any of a number administration routes, exhibits advantages over previously administered compounds. | 12-18-2014 |
20150038452 | Methods of Treating Optic Disorders - The present invention relates to methods for treating optic disorders or for reducing or alleviating the signs, symptoms, or pathological conditions related to such optic disorders. In particular, methods are provided for treating optic disorders, or reducing the symptoms thereof, the methods involving the administration of one or more downstream folate compounds and/or methyl-B12. In one particular embodiment, the method comprises administration of L-methylfolate. In other embodiments, the method involves administering both L-methylfolate and methyl-B12. In still further embodiments, the method further involves reducing dietary intake of folic acid. In certain embodiments, the method further involves identifying a subject organism with a malfunction in one or more of the folate or B4 cycles. In certain embodiments, such a malfunction is one or more of the C677T and A1298C mutations. In still further embodiments, the method further involves identifying a subject organism that is deficient in vitamins B-12 and D3 but which possesses excess homocysteine. | 02-05-2015 |
20150038453 | PREPARATION FOR USE OF ASPARTATE AND VITAMIN B12 OR BIOTIN FOR REGULATING KETONE BODIES - It has been found that high amounts of aspartate equivalents in combination with vitamin B12 and/or biotin, especially in relative absence of glutamate equivalents, improve the metabolism of ketobodies and/or lactate in a mammal's body, especially in diseased or traumatic conditions. As a result, levels of ketobodies and lactate can be decreased and unphysicologically high acidity normalised. Thus, it is an object of the invention to provide an enteral nutritional or a pharmaceutical composition for the treatment and/or prevention of disturbed ketone and lactate metabolism, i.e. elevated concentrations of ketone bodies, lactate and/or other organic acids and/or insufficient pH homeostasis, especially elevated concentrations of ketone bodies and/or lactate, in a mammal's blood, wherein the composition comprises high amounts of aspartate equivalents in combination with vitamin B12 and/or biotin, preferably in relative absence of glutamate equivalents. | 02-05-2015 |
20150065448 | METHODS OF TREATING AMYLOIDOSES WITH VITAMIN B12 AND DIAGNOSTIC TEST FOR DETECTING THE PRESENCE OF AMYLOID-BETA PEPTIDES - Embodiments of the invention include methods of using vitamin B12 to influence amyloid-beta peptide aggregation. A preferred method comprises contacting at least one amyloid-beta peptide oligomer formed from a plurality of amyloid-beta peptide monomers with an effective amount of vitamin B12, the effective amount being sufficient to stimulate dissociation of the amyloid-beta peptide monomers from the amyloid-beta peptide oligomer or fibril. Also provided are methods of treating Alzheimer's disease and diagnostic tests for detecting the presence of amyloid-beta peptides. | 03-05-2015 |
20150065449 | Treating Amyloidoses With A Vitamin B12 Composition Including Melatonin, Resveratrol, and EGCG - A method of treating amyloid-beta peptide aggregation in a subject includes contacting at least one amyloid-beta peptide oligomer formed from a plurality of amyloid-beta peptide monomers with a composition containing melatonin, resveratrol, EGCG, and an effective amount of vitamin B12. The effective amount of vitamin B12 being sufficient to stimulate dissociation of the amyloid-beta peptide monomers from the at least one amyloid-beta peptide oligomer. The composition may be used to treat amyloidosis, including Alzheimer's disease. | 03-05-2015 |
20150105343 | NUCLEOSIDE SUPPLEMENTATION TO PROMOTE CELLULAR FUNCTION, GENETIC STABILITY AND REGENERATIVE APPLICATIONS - In various embodiments, a cell culture medium, or a nucleoside cocktail transmission (NCT) medium for the culture of stem cells with improved genetic stability, cellular function and regeneration ability is provided. Illustrative culture media comprise a basal culture medium for stem cells, where the culture medium is supplemented with one or more nucleoside triphosphates (e.g., dNTPs and/or NPs) or one or more precursors thereof. Illustrative NCT media comprise a delivery vehicle (e g. skin creams or other vehicle) containing one or more nucleoside triphosphates (e.g., dNTPs and/or NPs) or one or more precursors thereof. The NCT medium provides, inter alia, direct delivery of nucleoside cocktails into human tissues (such as skin) for regenerative, cosmetic and/or therapeutic purposes. | 04-16-2015 |
20150133397 | METHOD OF REDUCING FASTING INSULIN LEVELS IN MTHFR GENE DEFICIENT SUBJECTS WITH NORMAL TO SLIGHTLY ELEVATED HEMOGLOBIN A1C - A method of treatment for reducing elevated fasting insulin levels of subjects with a MTHFR gene deficiency is provided. The method includes first determining whether a subject has an MTHFR gene deficiency. Once a subject has been found to have the MTHFR gene deficiency, the fasting insulin levels of the subject are determined. If the subject has a high fasting insulin level, the subject is administered an active folate. | 05-14-2015 |
20150141366 | EFFECTIVE TREATMENT OF ESOPHOGEAL ADENOCARCINOMA USING TRICIRIBINE AND RELATED COMPOUNDS - The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat esophogeal adenocarcinoma by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug. | 05-21-2015 |
20150306033 | PHARMACEUTICAL COMPOSITION CONTAINING VITAMIN B12 - A pharmaceutical composition for intranasal administration for human subjects includes vitamin B12 and a pharmaceutically acceptable carrier. The vitamin B12 particles are dispersed in a hydrophobic continuous phase as the pharmaceutically acceptable carrier. The dispersion of solid vitamin B12 particles (crystals or amorphic) in a hydrophobic continuous phase displays very satisfactory bioavailability. Also, the intense red colour is reduced significantly, making the pharmaceutical composition acceptable for intranasal use. | 10-29-2015 |
20150320784 | EFFECTIVE TREATMENT OF TUMORS AND CANCER WITH TRICIRIBINE AND RELATED COMPOUNDS - The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat tumors and cancer by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug. | 11-12-2015 |
20150328318 | Stabilization of Vitamin B12 - The invention relates to preparations comprising vitamin B | 11-19-2015 |
20150342931 | SPIROCYCLIC CETP INHIBITORS - Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis. The chemical compounds that are disclosed cholesterol ester transfer protein (CETP) and are expected to have utility in raising HDL-C, lowering LDL-C, and in the treatment and prevention of atherosclerosis. | 12-03-2015 |
20150359813 | EFFECTIVE TREATMENT OF ESOPHOGEAL ADENOCARCINOMA USING TRICIRIBINE AND RELATED COMPOUNDS - The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat esophogeal adenocarcinoma by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug. | 12-17-2015 |
20150366971 | VITAMIN PREPARATION - The invention relates to a vitamin preparation, especially for application to She skin, containing
| 12-24-2015 |
20160000716 | METHOD OF TREATING VITAMIN B12 DEFICIENCY - The present invention relates generally to Vitamin B12 pharmaceutical composition and method of using the same for the treatment of Vitamin B12 deficiency and the various disorders that are related to such deficiency. In particular embodiments, the present invention is directed towards treatment methods comprising sublingual or buccal administration of a Vitamin B12 composition useful in the practice of such treatment. The present invention features compositions that include one or more Vitamin B 12 compounds, propylene glycol, a solid adsorbent and a solid water-soluble excipient, wherein the Vitamin B 12 compounds are in a propylene glycol solution. | 01-07-2016 |
20160022710 | PRENATAL AND LACTATION SUPPLEMENTS TO ENHANCE CENTRAL NERVOUS SYSTEM DEVELOPMENT OF OFFSPRING - Disclosed are prenatal and lactation supplements for pregnant women and lactating women, which include a combination of RRR-alpha-tocopherol, docosahexaenoic acid (DHA), trans-lutein, phospholipids, and at least one nuclear receptor activating ligand other than RRR-alpha-tocopherol, DHA, and trans-lutein. The supplements may enhance central nervous system development in a fetus or breast-feeding newborn infant. | 01-28-2016 |
20160022712 | Administration of Nicotinamide Mononucleotide in the Treatment of Disease - Disclosed are methods and compositions related to methods of treating, ameliorating, mitigating, slowing, arresting, preventing or reversing various diseases and conditions, including age-related obesity, age-related increases in blood lipid levels, age-related decreases in insulin sensitivity, age-related decreases in memory function, and age-related changes in eye function such as macular degeneration. The methods comprise administering nicotinamide mononucleotide (NMN) to a subject. In some embodiments, the administration can be oral administration. Also disclosed are pharmaceutical compositions comprising NMN. | 01-28-2016 |
20160030463 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INSULIN RESISTANCE OR ABNORMAL LEVELS OF CIRCULATING LIPIDS IN A MAMMAL - The present invention includes compositions useful for treating or preventing abnormal levels of circulating lipids in a mammal in need thereof, and methods using same. The compositions of the invention normalize levels of circulating lipids in the mammal, and do not cause the toxic side-effects known to occur with currently available lipid-managing medications, such as monotherapies using niacin or fibrates. | 02-04-2016 |
20160058752 | TOPICAL PERIPHERAL NEURO-AFFECTIVE (TPNA) THERAPY FOR NEUROPATHIC CONDITIONS - Formulations and methods of treating peripheral neuropathic conditions in humans is disclosed. | 03-03-2016 |
20160074420 | ORAL B12 THERAPY - Methods of normalizing vitamin B | 03-17-2016 |
20160106713 | NITRIC OXIDE SCAVENGERS - Therapeutic compositions capable of removing excess nitric oxide are provided. The therapeutic compositions include nitronyl nitroxide monoradicals, B12 derivatives, flavonoid derivatives, the like and combinations thereof. The therapeutic compositions can be utilized in a number of suitable applications, such as to prevent or treat intradialytic hypotension during dialysis. | 04-21-2016 |
20160143926 | COMPOSITIONS AND METHODS FOR THE PREPARATION OF KIDNEY PROTECTIVE AGENTS COMPRISING AMIFOSTINE AND AMINO ACIDS - This invention relates to composition and method of preparation of AminoMedix™ comprising of Amifostine, at least one amino acid (Arginine, Lysine, Histidine) with or without other pharmaceutically active compounds. The AminoMedix™ composition can be applied for kidney protection during therapy using radiolabeled and non-radiolabeled compounds, contrast agents, chemotherapeutics, antibiotics and drugs showing nephrotoxic effect. | 05-26-2016 |
20160158190 | Methods and Compositions for Inhibition of ATR and FANCD2 Activation - This invention is announcing a composition of flavonoid skeleton in the formula I or formula II compound, wherein each of the substituents is given the definition as set forth in the specification and claims. This composition have the capacity to treating or preventing a virus infection in a subject. | 06-09-2016 |
20160250215 | QUINAZOLINE COMPOUNDS | 09-01-2016 |
20190145988 | PERSONALISED NUTRIENT DOSING WITH ON-GOING FEEDBACK LOOP | 05-16-2019 |